


DNA Methylation as a Prognostic Indicator of Liver Hepatocellular Carcinoma (LIHC)

Harinarayana Mellacheruvu and Tony Zhang

Background

- **Clinicopathological information:** age, gender, cancer stage...
 - Usually used for prognosis, but does not provide enough details about the cancer
- **DNA Methylation**
 - A biologically-significant and reliable biomarker which is promising for prognosis




(https://www.mdpi.com/cells/cells-08-00953/article_deploy/html/images/cells-08-00953-g001-550.jpg)

Challenges


- **Survival analysis** estimates the survival time of a patient
- Challenges with survival analysis on **high-dimensional data**
 - Censorship of survival data
 - Censoring rate of TCGA-LIHC data: 35% (132 alive, 245 dead)
 - High-dimensional data but **small sample size**
 - Dimension of data: 377 samples by 369,561 probes
 - Models likely to suffer from overfitting

Methods: Data Preprocessing



Methods: Identifying Differentially Methylated Positions (DMPs)


- 1) Comparing m-values of 50 pairs of tumor and normal samples
- 2) Using the dmpFinder function to find DMPs
- 3) Keeping probes with FDR corrected p-values < 0.05
- 4) Results: 213,392 DMPs



PCA plot of 377 tumor (green) and 50 normal (purple) samples

Methods: Marker Selection

- Step 1: Build a univariate **cox model** to select a smaller subset of probes to do further testing with
- Step 2: Build a multivariate **cox model** to select a significant combination of specific methylated CpG sites
- Elastic Penalty because many covariates (CpG sites)
- Data: **M Values** at specific CpG sites for patients
 - M values = $\log(\text{Methylated Signal} / \text{Unmethylated signal})$






Methods: Model Training and Validation

- Performed $\frac{2}{3}$ - $\frac{1}{3}$ training test split
- 5-fold cross-validation done to select best model
- Ultimately, 4288 probes were selected from multivariate cox hazard model

Results: DMPs in normal and tumor tissues

- Methylation measured using beta values
- Risk scores assigned to samples based on Cox hazard model
- Stratify LIHC patients into high and low risk based on methylation signal






Discussion

- **Takeaways:**

- Looked at differentially methylated CpG sites as a prognostic indicator in liver cancer
- Use methylation signal, specifically M values, we can stratify patients into high and low risk categories
- Methylation vs Cancer Stage

- **Next Steps:**

- Analyze methylation signals as prognostic indicator using cfDNA
- Validation of model on independent data set



Acknowledgements



PI: Jasmine Zhou



Direct Mentor: Ran Hu

The Zhou Lab

UCLA David Geffen School of Medicine